| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Keila N. Lopez | Baylor College of Medicine | NIH/NHLBI (K23HL127164, Early Career Grant for improving transition from pediatric to adult care)* | None | None | None | None | None | None |
| Shabnam Peyvandi | UCSF | NIH/NINDS (K23 Fetal Markers of Neurodevelopment Outcome in congenital heart disease) † | None | None | None | None | None | None |
| Carissa Baker‐Smith | Nemours‐Alfred I. DuPont Hospital for Children | None | None | None | None | None | None | None |
| Glenn Flores | Connecticut Children's Medical Center, University of Connecticut | None | None | None | None | None | None | None |
| Michelle Gurvitz | Boston Children's Hospital | None | None | None | None | None | None | None |
| Tara Karamlou | Cleveland Clinic Foundation | None | None | None | None | None | None | None |
| Flora Nunez Gallegos | Stanford University School of Medicine | None | None | None | None | None | None | None |
| Sara Pasquali | University of Michigan | None | None | None | None | None | None | None |
| Angira Patel | Lurie Children's Hospital of Chicago | None | None | None | None | None | None | None |
| Jennifer K. Peterson | Johns Hopkins University | None | None | None | None | None | None | None |
| Jason L. Salemi | University of South Florida | None | None | None | None | None | None | None |
| Clyde Yancy | Northwestern University | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the disclosure questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be significant if (1) the person receives $10 000 or more during any 12‐month period, or 5% or more of the person’s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be modest if it is less than significant under the preceding definition.
*
Modest.
†
Significant.